

Juan Gimeno Blanes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/391574/publications.pdf>

Version: 2024-02-01

132
papers

15,603
citations

66250

44
h-index

19470

122
g-index

154
all docs

154
docs citations

154
times ranked

14100
citing authors

#	ARTICLE	IF	CITATIONS
1	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. <i>Cardiovascular Research</i> , 2022, 118, 1466-1478.	1.8	20
2	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. <i>European Heart Journal</i> , 2022, 43, 3053-3067.	1.0	41
3	Impact of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. <i>ESC Heart Failure</i> , 2022, 9, 2189-2198.	1.4	6
4	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 134-142.	1.8	3
5	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. <i>ESC Heart Failure</i> , 2021, 8, 95-105.	1.4	23
6	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. <i>Heart Rhythm</i> , 2021, 18, 79-87.	0.3	26
7	Towards an Enhanced Tool for Quantifying the Degree of LV Hyper-Trabeculation. <i>Journal of Clinical Medicine</i> , 2021, 10, 503.	1.0	4
8	Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. <i>International Journal of Cardiology</i> , 2020, 307, 101-108.	0.8	56
9	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 302, 124-130.	0.8	23
10	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. <i>JAMA Cardiology</i> , 2020, 5, 73.	3.0	69
11	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the <i>TTN</i> Gene. <i>Circulation: Heart Failure</i> , 2020, 13, e006832.	1.6	75
12	Trabeculated Myocardium in Hypertrophic Cardiomyopathy: Clinical Consequences. <i>Journal of Clinical Medicine</i> , 2020, 9, 3171.	1.0	5
13	ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. <i>ESC Heart Failure</i> , 2020, 7, 3013-3021.	1.4	19
14	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 759-769.	6.3	481
15	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2020, 7, 3601-3609.	1.4	11
16	ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1304.	0.6	12
17	Genetic Factors Involved in Cardiomyopathies and in Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1702.	1.0	4
18	Genetics of feline hypertrophic cardiomyopathy. <i>Clinical Genetics</i> , 2020, 98, 203-214.	1.0	10

#	ARTICLE	IF	CITATIONS
19	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1076-1096.	2.9	96
20	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, heartjnl-2018-313700.	1.2	31
21	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1366-1367.	1.2	0
22	Sex-related differences in cardiomyopathies. <i>International Journal of Cardiology</i> , 2019, 286, 239-243.	0.8	39
23	A study of the pathogenicity of variants in familial heart disease. The value of cosegregation. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1724-1735.	0.0	2
24	Miocardopatía hipertrófica. <i>Medicina Clínica</i> , 2018, 150, 434-442.	0.3	5
25	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. <i>European Heart Journal</i> , 2018, 39, 1784-1793.	1.0	94
26	Genetics of hypertrophic cardiomyopathy: A review of current state. <i>Clinical Genetics</i> , 2018, 93, 3-14.	1.0	130
27	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2457-2467.	1.2	59
28	D242N, a KV7.1 LQTS Mutation Uncovers a KEY Residue for IKS Voltage Dependence. <i>Biophysical Journal</i> , 2018, 114, 307a.	0.2	0
29	Phenotypic Characterization of a Family With An In-frame Deletion in the DMD Gene and Variable Penetrance. <i>Current Gene Therapy</i> , 2018, 18, 246-251.	0.9	2
30	Factores modificadores del fenotipo en la miocardopatía hipertrófica. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 770-771.	0.6	0
31	Miocardopatía hipertrófica en 2018: ¿en qué punto estamos?. <i>CardiCore</i> , 2018, 53, 148-151.	0.0	1
32	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. <i>Heart</i> , 2017, 103, 672-678.	1.2	71
33	COMPUTER ASSISTED RETINAL VESSEL TORTUOSITY EVALUATION IN NOVEL MUTATION FABRY DISEASE. <i>Retina</i> , 2017, 37, 592-603.	1.0	17
34	Value of the "Standing Test" in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 907-914.	0.4	4
35	Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 240, 265-270.	0.8	66
36	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 105-114.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Valor del «test de bipedestación» en el diagnóstico y la evaluación de la respuesta al tratamiento con bloqueadores beta en el síndrome de QT largo. Revista Española De Cardiología, 2017, 70, 907-914.	0.6	2
38	Comentarios a los nuevos criterios internacionales para la interpretación del electrocardiograma del deportista. Revista Española De Cardiología, 2017, 70, 983-990.	0.6	0
39	D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence. Journal of Molecular and Cellular Cardiology, 2017, 110, 61-69.	0.9	11
40	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, 2017, 248, 232-238.	0.8	41
41	IKs Computational Modeling to Enforce the Investigation of D242N, a KV7.1 LQTS Mutation. , 2017, , .		0
42	An R1632C variant in the SCN5A gene causing Brugada syndrome. Molecular Medicine Reports, 2016, 13, 4677-4680.	1.1	3
43	Unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in <sc>FHL1</sc>. Clinical Genetics, 2016, 90, 171-176.	1.0	19
44	Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?. Expert Opinion on Orphan Drugs, 2016, 4, 1199-1206.	0.5	0
45	Factor de transcripción TBX1 en el remodelado cardíaco asociado al infarto de miocardio. Revista Española De Cardiología, 2016, 69, 1042-1050.	0.6	1
46	The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. Revista Española De Cardiología (English Ed), 2016, 69, 1042-1050.	0.4	0
47	Mutation in <sc>JPH2</sc> cause dilated cardiomyopathy. Clinical Genetics, 2016, 90, 468-469.	1.0	20
48	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	1.2	340
49	La importancia del estudio familiar y genético: la mutación p.L3778F en el receptor de la rianodina probablemente no cause un fenotipo tan grave. Revista Española De Cardiología, 2016, 69, 702-704.	0.6	1
50	Penetrancia familiar en la parada cardíaca en ausencia de cardiopatía aparente: observaciones del estudio FIV-Gen. Cardiaccore, 2016, 51, 30-36.	0.0	2
51	The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. Revista Española De Cardiología (English Ed), 2016, 69, 702-704.	0.4	0
52	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	19
53	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	1.0	757
54	Hypertrophic or hypertensive cardiomyopathy?. International Journal of Cardiology, 2016, 203, 891-892.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. Revista Espanola De Cardiologia (English Ed), 2016, 69, 300-309.	0.4	14
56	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.3	60
57	Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (<sc>HCM</sc>) Tj ETQq1 1 0,784314 rgBT/O	2.9	114
58	Author's reply. Europace, 2015, 17, 334-337.	0.7	0
59	A mutation in the Zâ€line Cypher/ZASP protein is associated with arrhythmogenic right ventricular cardiomyopathy. Clinical Genetics, 2015, 88, 172-176.	1.0	28
60	Phenotype and prognostic correlations of the converter region mutations affecting the Î² myosin heavy chain. Heart, 2015, 101, 1047-1053.	1.2	54
61	New haplotype of Fabry disease among patients screened for left ventricular hypertrophy of unknown cause. Molecular Genetics and Metabolism, 2015, 114, S29-S30.	0.5	0
62	Arrhythmogenic right ventricular cardiomyopathy. Lancet, The, 2015, 385, 662.	6.3	4
63	Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm, 2015, 12, 766-773.	0.3	111
64	Unexpected autopsy findings after sudden cardiac death: Cardiovascular myxoedema and endocardial fibroelastosis. International Journal of Cardiology, 2015, 182, 281-283.	0.8	4
65	Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). American Journal of Cardiology, 2015, 116, 894-899.	0.7	46
66	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	1.0	75
67	MutaciÃ³n p.Arg14del en fosfolambÃ¡n en una familia espaÃ±ola con miocardiopatÃ­a arritmogÃ©nica: evidencia de una mutaciÃ³n europea fundadora. Revista Espanola De Cardiologia, 2015, 68, 346-349.	0.6	7
68	Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 346-349.	0.4	6
69	Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. Revista Espanola De Cardiologia (English Ed), 2015, 68, 861-868.	0.4	2
70	Fenotipo heterogÃ©neo del sÃ­ndrome de QT largo causado por la mutaciÃ³n KCNH2-H562R: importancia del estudio genÃ©tico familiar. Revista Espanola De Cardiologia, 2015, 68, 861-868.	0.6	6
71	A new<i>KCNQ1</i> mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. Cardiovascular Research, 2015, 107, 613-623.	1.8	67
72	Hypertrophic Obstructive Cardiomyopathy and Takotsubo Syndrome: Could They Coexist?. Archives of Cardiovascular Imaging, 2015, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
73	CRT-177 Ulnar Artery, is it as Safe as the Radial for Cardiac Catheterization?. JACC: Cardiovascular Interventions, 2014, 7, S32.	1.1	1
74	Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype. Medicina Clínica, 2014, 142, 497-504.	0.3	5
75	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
76	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	1.0	848
77	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	1.0	154
78	Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. Europace, 2014, 16, 1838-1846.	0.7	87
79	A study of the <scp><i>SCN5A</i></scp> gene in a cohort of 76 patients with Brugada syndrome. Clinical Genetics, 2013, 83, 530-538.	1.0	17
80	Eco-Doppler de ejercicio en pacientes con miocardiopatía hipertrófica. Factores determinantes de la limitación funcional. Revista Española De Cardiología, 2013, 66, 98-103.	0.6	12
81	Exercise Eco-Doppler in Hypertrophic Cardiomyopathy Patients. Determinant Factors of Exercise Intolerance. Revista Española De Cardiología (English Ed), 2013, 66, 98-103.	0.4	4
82	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	1.0	346
83	Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nature Medicine, 2013, 19, 193-201.	15.2	296
84	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	1.0	84
85	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	1.0	2,436
86	Atypical Cause of Syncope in Patients with Brugada Syndrome. The European Journal of Cardiovascular Medicine, 2013, 11, .	1.0	0
87	Somatic <i>MYH7</i>, <i>MYBPC3</i>, <i>TPM1</i>, <i>TNNT2</i> and <i>TNNI3</i> Mutations in Sporadic Hypertrophic Cardiomyopathy. Circulation Journal, 2013, 77, 2358-2365.	0.7	15
88	Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: An Opportunity to Be Taken. Revista Española De Cardiología (English Ed), 2012, 65, 314-318.	0.4	6
89	Ablación septal alcohólica en la miocardiopatía hipertrófica, una oportunidad para aprovechar. Revista Española De Cardiología, 2012, 65, 314-318.	0.6	11
90	Percutaneous coronary intervention with rotational atherectomy for severely calcified unprotected left main: Immediate and two-year follow-up results. Catheterization and Cardiovascular Interventions, 2012, 80, 215-220.	0.7	36

#	ARTICLE	IF	CITATIONS
91	Short QT and dilated cardiomyopathy. A phenotype with a good prognosis?. International Journal of Cardiology, 2011, 151, 356-357.	0.8	0
92	Hypertrophic cardiomyopathy or storage cardiomyopathy? Role of genetics to predict outcome. International Journal of Cardiology, 2011, 151, 380-381.	0.8	0
93	Modelo de intervenci3n coronaria percut4nea primaria en la Regi3n de Murcia. Revista Espanola De Cardiologia Suplementos, 2011, 11, 28-34.	0.2	2
94	Efficacy of percutaneous closure of patent foramen ovale: comparison among three commonly used occluders. Heart, 2011, 97, 394-399.	1.2	42
95	Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart, 2010, 96, 1980-1984.	1.2	58
96	Characteristics of Sudden Death in Inherited Heart Disease. Revista Espanola De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	2
97	Intervencionismo coronario en lesiones severamente calcificadas mediante aterectom4a rotacional y stent liberador de paclitaxel: resultados tras un a4o de seguimiento. Revista Espanola De Cardiologia, 2010, 63, 107-110.	0.6	27
98	Caracter4sticas de la muerte s4bita en las cardiopat4as hereditarias. Revista Espanola De Cardiologia, 2010, 63, 268-276.	0.6	11
99	Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 82-90.	0.4	42
100	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 2599-2605.	1.0	160
101	Penetrance and Risk Profile in Inherited Cardiac Diseases Studied in a Dedicated Screening Clinic. American Journal of Cardiology, 2009, 104, 406-410.	0.7	38
102	Heat stroke, an unusual trigger of Brugada electrocardiogram. American Journal of Emergency Medicine, 2009, 27, 634.e1-634.e3.	0.7	11
103	Unusual presentation of acute coronary syndrome. Bilateral coronary dissection after car accident. American Journal of Emergency Medicine, 2009, 27, 1024.e3-1024.e5.	0.7	7
104	Embolia coronaria tras implante percut4neo de pr4tesis valvular a4rtica. Revista Espanola De Cardiologia, 2009, 62, 1074-1075.	0.6	4
105	Gadolinium-Enhanced Cardiovascular Magnetic Resonance and Exercise Capacity in Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 853-860.	0.4	1
106	Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. Journal of the American College of Cardiology, 2008, 51, 818-825.	1.2	256
107	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. American Heart Journal, 2008, 156, 85-91.	1.2	80
108	Prognostic value of the Thrombolysis in Myocardial Infarction risk score in a unselected population with chest pain. Construction of a new predictive model. American Journal of Emergency Medicine, 2008, 26, 439-445.	0.7	8

#	ARTICLE	IF	CITATIONS
109	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. <i>Journal of Cardiac Failure</i> , 2008, 14, 414-419.	0.7	33
110	Detection and estimation of T wave alternans with matched filter and nonparametric bootstrap test. , 2008, , .		2
111	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2419-2426.	1.2	167
112	Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2399-2403.	1.2	254
113	Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 537-544.	0.4	11
114	In-Hospital and Long-Term Mortality in Women With Acute Myocardial Infarction Treated by Primary Angioplasty. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 1113-1122.	0.4	16
115	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2006, 27, 3073-3073.	1.0	34
116	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2006, 98, 515-519.	0.7	42
117	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2006, 27, 1933-1941.	1.0	352
118	Heterophile antibodies produce spuriously elevated concentrations of cardiac Troponin I in patients with <i>Legionella pneumophila</i> . <i>Clinical Biochemistry</i> , 2005, 38, 584-587.	0.8	14
119	Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. <i>Heart</i> , 2005, 92, 785-791.	1.2	235
120	Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. <i>Heart</i> , 2005, 91, 920-925.	1.2	126
121	Natural history and familial characteristics of isolated left ventricular non-compaction. <i>European Heart Journal</i> , 2005, 26, 187-192.	1.0	427
122	Backscatter evaluation of myocardial functional and textural findings in children with right ventricular pressure and/or volume overload. <i>American Journal of Cardiology</i> , 2004, 93, 594-597.	0.7	12
123	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. <i>Journal of the American College of Cardiology</i> , 2004, 44, 398-405.	1.2	72
124	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 42, 873-879.	1.2	484
125	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. <i>Journal of Clinical Investigation</i> , 2003, 111, 209-216.	3.9	169
126	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. <i>Journal of Clinical Investigation</i> , 2003, 111, 209-216.	3.9	278

#	ARTICLE	IF	CITATIONS
127	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. <i>Journal of Clinical Investigation</i> , 2003, 111, 925-925.	3.9	0
128	Reversal of acute pulmonary oedema with beta-blockers in hypertrophic cardiomyopathy. <i>European Journal of Echocardiography</i> , 2003, 4, 71-2.	2.3	0
129	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1445-1450.	1.2	285
130	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. <i>Lancet, The</i> , 2001, 357, 420-424.	6.3	436
131	Soluble and Particulate Organophosphorus Neuropathy Target Esterase in Brain and Sciatic Nerve of the Hen, Cat, Rat, and Chick. <i>Journal of Neurochemistry</i> , 1993, 61, 2164-2168.	2.1	16
132	Evidence for reciprocal network interactions between injured hearts and cancer. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2